Figure 1

Nilotinib inhibits the proliferation of CD4⁺CD25⁺ T cells and CD4⁺CD25^- T cells in a dose-dependent manner. CD4⁺CD25⁺ T cells or CD4+CD25^- T cells were labeled with CFSE and cultured with different concentrations of nilotinib as indicated. After 4 days incubation, cells were harvested and stained with CD25 and FoxP3. Cell division was assessed by the dilution of CFSE. Panels A and B show the combined results from four independent experiments with similar results. Displayed are mean values ± SD. Panels C and D display the results of a representative experiment.